EyeGene: EG-COVID Will Be Starting Point For Other mRNA Vaccines
Key Is To Verify Novel Platform
Executive Summary
EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.